Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Recently, early graft loss has become very rare in living-related kidney transplantation (LKT) as a result of decreased risk of hyperacute rejection and improvements in immunosuppressive regimens. Post-transplant acute thrombotic microangiopathy (TMA) is a rare, multi-factorial disease that often occurs shortly after kidney transplantation and is usually resistant to treatment with dismal renal outcomes. The complement genetic variants may accelerate the development of TMA. However, the complement genetic test was seldom performed in unknown native kidney disease recipients scheduled for LKT.

Case Presentation: We reported three cases of unknown native kidney diseases who had fulminant TMA in the allograft shortly after LKT. Both the donors and the recipients were noted to carry complement genetic variants, which were identified by genetic testing after transplantation. However, all recipients were refractory to treatment and had allograft loss within 3 months after LKT.

Conclusion: This case series highlights the suggestion to screen complement gene variants in both the donors and the recipients with unknown native kidney diseases scheduled for LKT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284761PMC
http://dx.doi.org/10.1186/s12882-022-02868-7DOI Listing

Publication Analysis

Top Keywords

kidney transplantation
12
complement genetic
12
unknown native
12
native kidney
12
early graft
8
graft loss
8
acute thrombotic
8
thrombotic microangiopathy
8
complement gene
8
gene variants
8

Similar Publications

Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.

View Article and Find Full Text PDF

Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.

Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.

View Article and Find Full Text PDF

Out of chaos, comes tolerance: targeting the T cells driving antibody-mediated rejection.

Kidney Int

September 2025

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio, USA; Transplant Center, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:

View Article and Find Full Text PDF

Felzartamab: a magic bullet to treat microvascular rejection?

Kidney Int

September 2025

Immunopathology Research Laboratory, Department of Pathology, Boston, Massachusetts, USA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.

View Article and Find Full Text PDF